Ignite Creation Date:
2024-05-06 @ 7:49 PM
Last Modification Date:
2024-10-26 @ 3:14 PM
Study NCT ID:
NCT06143371
Status:
RECRUITING
Last Update Posted:
2023-12-01
First Post:
2023-11-16
Brief Title:
A Study to Investigate the Safety and Tolerability of CAN10 Antibody in Healthy Subjects and in Subjects With Plaque Psoriasis
Sponsor:
Cantargia AB
Organization:
Cantargia AB
Study Overview
Official Title:
A Phase I First-in-human Randomized Double-blind Placebo Controlled Study to Investigate the Safety Tolerability Pharmacokinetics and Pharmacodynamics of CAN10 an Anti-IL1RAP Monoclonal Antibody in Healthy Subjects and in Subjects With Mild to Moderate Plaque Psoriasis
Status:
RECRUITING
Status Verified Date:
2023-11
Last Known Status:
None
Delayed Posting:
No
If Stopped, Why?:
Not Stopped
Has Expanded Access:
False
If Expanded Access, NCT#:
N/A
Has Expanded Access, NCT# Status:
N/A
Acronym:
None
Brief Summary:
This is a first-in-human randomized double- blind placebo-controlled dose escalation study to investigate how different doses of CAN10 are tolerated taken up by the body and how long CAN10 stays in the body In the first part of the study the single ascending dose SAD cohorts CAN10 will be given as a single intravenous dose to healthy subjects In the second part of the study the multiple ascending dose MAD cohorts CAN10 will be given as repeated subcutaneous doses to participants with mild to moderate plaque psoriasis
Detailed Description:
None
Study Oversight
Has Oversight DMC:
None
Is a FDA Regulated Drug?:
False
Is a FDA Regulated Device?:
False
Is an Unapproved Device?:
None
Is a PPSD?:
None
Is a US Export?:
None
Is an FDA AA801 Violation?:
None
Secondary IDs
| Secondary ID | Type | Domain | Link |
|---|---|---|---|
| 2023-504450-35 | EUDRACT_NUMBER | None | None |